DK563487A - Stabil farmaceutisk komposition af rekombinant beta-interferon - Google Patents
Stabil farmaceutisk komposition af rekombinant beta-interferonInfo
- Publication number
- DK563487A DK563487A DK563487A DK563487A DK563487A DK 563487 A DK563487 A DK 563487A DK 563487 A DK563487 A DK 563487A DK 563487 A DK563487 A DK 563487A DK 563487 A DK563487 A DK 563487A
- Authority
- DK
- Denmark
- Prior art keywords
- stable pharmaceutical
- pharmaceutical composition
- beta interferon
- recombinant beta
- ionic polymeric
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000003996 Interferon-beta Human genes 0.000 title 1
- 108090000467 Interferon-beta Proteins 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 239000003599 detergent Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92342386A | 1986-10-27 | 1986-10-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK563487D0 DK563487D0 (da) | 1987-10-27 |
| DK563487A true DK563487A (da) | 1988-04-28 |
Family
ID=25448670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK563487A DK563487A (da) | 1986-10-27 | 1987-10-27 | Stabil farmaceutisk komposition af rekombinant beta-interferon |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0270799B1 (da) |
| JP (1) | JPS63179833A (da) |
| AT (1) | ATE111744T1 (da) |
| AU (2) | AU8019187A (da) |
| CA (1) | CA1294215C (da) |
| DE (1) | DE3750574T2 (da) |
| DK (1) | DK563487A (da) |
| FI (1) | FI95002C (da) |
| NO (1) | NO175704C (da) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
| US4961969A (en) * | 1987-05-11 | 1990-10-09 | Cetus Corporation | Process for recovering microbially produced interferon-β |
| US5151265A (en) * | 1987-11-03 | 1992-09-29 | Genentech, Inc. | Gamma interferon formulation |
| US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
| IL89662A (en) * | 1989-03-19 | 1997-11-20 | Interpharm Lab Ltd Kiryat Weiz | Pharmaceutical compositions comprising interferon-beta |
| US6586222B1 (en) | 1989-08-16 | 2003-07-01 | Chiron Corporation | Recombinant PR-3 and compositions thereof |
| US5843693A (en) * | 1989-08-16 | 1998-12-01 | Chiron Corporation | Assay method for screening for inhibitors of proTNF conversion |
| US5998378A (en) * | 1989-08-16 | 1999-12-07 | Chiron Corporation | Compositions for the inhibition of TNF hormone formation and uses thereof |
| US20030171292A1 (en) | 1992-06-01 | 2003-09-11 | Creasey Abla A. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| CA2147466A1 (en) * | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
| CA2185162A1 (en) | 1994-03-07 | 1995-09-14 | Robert F. Halenback (Deceased) | Compositions for the inhibition of tnf formation and uses thereof |
| IT1272252B (it) | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
| US5556771A (en) * | 1995-02-10 | 1996-09-17 | Gen-Probe Incorporated | Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification |
| GB9506051D0 (en) * | 1995-03-24 | 1995-05-10 | Univ Singapore | Gene expression |
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| CA2304808C (en) | 1997-09-23 | 2011-03-22 | Michael Tschope | Liquid interferon-.beta. formulations |
| US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
| US7544354B2 (en) | 2000-10-27 | 2009-06-09 | Novartis Vaccines And Diagnostics | Methods of protein purification and recovery |
| AU3070702A (en) | 2000-11-07 | 2002-05-21 | Chiron Corp | Stabilized inteferon compositions |
| US7101693B2 (en) | 2001-09-07 | 2006-09-05 | Brigham Young University | Plasticized hydrophilic glasses for improved stabilization of biological agents |
| EP1446140A4 (en) | 2001-10-15 | 2007-03-07 | Novartis Vaccines & Diagnostic | TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR) |
| EP1844815B1 (en) | 2003-11-04 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers |
| EP1680141B8 (en) | 2003-11-04 | 2011-01-12 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for solid tumors expressing the cd40 cell-surface antigen |
| CA2544951A1 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma |
| PT1694360E (pt) | 2003-11-04 | 2010-12-13 | Novartis Vaccines & Diagnostic | Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos |
| ATE474598T1 (de) | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| US9550811B2 (en) | 2010-12-02 | 2017-01-24 | Bionor Immuno As | Peptide scaffold design |
| US9493514B2 (en) | 2011-01-06 | 2016-11-15 | Bionor Immuno As | Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes |
| JP6310909B2 (ja) | 2012-06-06 | 2018-04-11 | ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ | 免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド |
| UA105278C2 (ru) | 2012-09-06 | 2014-04-25 | Інститут Біології Клітини Нан України | Способ получения каталитически активных антител (абзимов) с сиалидазной активностью |
| WO2014176375A2 (en) | 2013-04-23 | 2014-10-30 | Cedars-Sinai Medical Center | Systems and methods for recording simultaneously visible light image and infrared light image from fluorophores |
| EP3096773B1 (en) | 2014-01-17 | 2020-07-01 | Cedars-Sinai Medical Center | Receptor targeting constructs and uses thereof |
| CA2937035A1 (en) | 2014-02-05 | 2015-08-13 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| CN106794175B (zh) | 2014-06-12 | 2020-06-09 | 西达-赛奈医疗中心 | 用于治疗癌症的组合物 |
| EP3173074A4 (en) | 2014-07-22 | 2018-03-07 | Lemonex Inc. | Composition for delivering bioactive material or protein, and use thereof |
| CN107106669A (zh) | 2014-11-04 | 2017-08-29 | 南加利福尼亚大学 | 用于治疗过度表达HIF‑1α的癌症的组合物和方法 |
| US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
| WO2016179326A1 (en) | 2015-05-05 | 2016-11-10 | The Regents Of The University Of California | H3.3 ctl peptides and uses thereof |
| AU2016315752B2 (en) | 2015-08-31 | 2021-08-05 | Cedars-Sinai Medical Center | Novel blood cell biomarker for late onset Alzheimer's disease |
| KR101843985B1 (ko) | 2016-02-09 | 2018-03-30 | 오토텔릭 엘엘씨 | 암을 치료하기 위한 조성물과 방법 |
| KR20180103816A (ko) | 2016-02-09 | 2018-09-19 | 오토텔릭 엘엘씨 | 췌장암을 치료하기 위한 조성물과 방법 |
| FI126979B (en) * | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and its use |
| US10927070B2 (en) | 2016-06-09 | 2021-02-23 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer |
| WO2018143787A1 (ko) | 2017-02-06 | 2018-08-09 | 주식회사 레모넥스 | 생리활성물질 전달체 |
| KR20180091768A (ko) | 2017-02-06 | 2018-08-16 | 주식회사 레모넥스 | 생리활성물질 전달체 |
| US20210121493A1 (en) | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| US11529338B2 (en) | 2017-08-22 | 2022-12-20 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer |
| KR102152348B1 (ko) | 2017-09-05 | 2020-09-08 | 주식회사 레모넥스 | 세포 운명 조절용 조성물 |
| ES2905483T3 (es) * | 2018-04-19 | 2022-04-08 | Lts Lohmann Therapie Systeme Ag | Sistema de microagujas para la aplicación de interferón |
| US11690799B2 (en) | 2018-04-19 | 2023-07-04 | Lts Lohmann Therapie-Systeme Ag | Microneedle system for applying interferon |
| KR102753455B1 (ko) | 2018-08-08 | 2025-01-10 | 세다르스-신나이 메디칼 센터 | 암 및 자가면역 질환을 치료하기 위한 조성물 및 방법 |
| JP2022512937A (ja) | 2018-11-08 | 2022-02-07 | セダーズ－シナイ メディカル センター | Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 |
| US20220073605A1 (en) | 2018-12-20 | 2022-03-10 | Cedars-Sinai Medical Center | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant |
| US20230109142A1 (en) | 2020-02-14 | 2023-04-06 | Immunor As | Corona virus vaccine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55102519A (en) * | 1979-01-31 | 1980-08-05 | Green Cross Corp:The | Stabilization of interferon |
| CA1190148A (en) * | 1981-10-13 | 1985-07-09 | Samuel S. Asculai | Interferon-containing compositions |
| JPS5910524A (ja) * | 1982-07-08 | 1984-01-20 | Toray Ind Inc | インタ−フエロン組成物およびその製造法 |
| US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
| US4992271A (en) * | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
| EP0107498B1 (en) * | 1982-10-25 | 1990-05-16 | Genentech, Inc. | Synergistic human interferon activity |
| EP0150067A3 (en) * | 1984-01-23 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
| US4680175A (en) * | 1984-02-07 | 1987-07-14 | Interferon Sciences, Inc. | Interferon administration vehicles |
| US4606917A (en) * | 1984-10-03 | 1986-08-19 | Syntex (U.S.A) Inc. | Synergistic antiviral composition |
| JPS61277633A (ja) * | 1985-05-31 | 1986-12-08 | Toray Ind Inc | インタ−フエロン組成物 |
-
1987
- 1987-10-16 CA CA000549489A patent/CA1294215C/en not_active Expired - Lifetime
- 1987-10-26 AT AT87115693T patent/ATE111744T1/de not_active IP Right Cessation
- 1987-10-26 NO NO874445A patent/NO175704C/no not_active IP Right Cessation
- 1987-10-26 FI FI874706A patent/FI95002C/fi not_active IP Right Cessation
- 1987-10-26 DE DE3750574T patent/DE3750574T2/de not_active Expired - Lifetime
- 1987-10-26 EP EP87115693A patent/EP0270799B1/en not_active Expired - Lifetime
- 1987-10-27 DK DK563487A patent/DK563487A/da not_active Application Discontinuation
- 1987-10-27 JP JP62271604A patent/JPS63179833A/ja active Pending
- 1987-10-27 AU AU80191/87A patent/AU8019187A/en not_active Abandoned
-
1992
- 1992-02-03 AU AU10633/92A patent/AU659127B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| EP0270799B1 (en) | 1994-09-21 |
| DE3750574T2 (de) | 1995-02-02 |
| AU659127B2 (en) | 1995-05-11 |
| DK563487D0 (da) | 1987-10-27 |
| DE3750574D1 (de) | 1994-10-27 |
| FI95002B (fi) | 1995-08-31 |
| NO175704C (no) | 1994-11-23 |
| FI874706L (fi) | 1988-04-28 |
| FI95002C (fi) | 1995-12-11 |
| JPS63179833A (ja) | 1988-07-23 |
| NO175704B (no) | 1994-08-15 |
| ATE111744T1 (de) | 1994-10-15 |
| NO874445L (no) | 1988-04-28 |
| CA1294215C (en) | 1992-01-14 |
| FI874706A0 (fi) | 1987-10-26 |
| AU1063392A (en) | 1992-03-19 |
| NO874445D0 (no) | 1987-10-26 |
| AU8019187A (en) | 1988-04-28 |
| EP0270799A1 (en) | 1988-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK563487A (da) | Stabil farmaceutisk komposition af rekombinant beta-interferon | |
| ATE74512T1 (de) | Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. | |
| KR100656125B1 (ko) | 장기 안정화 제제 | |
| US5766582A (en) | Stable, aqueous alfa interferon solution formulations | |
| ATE106247T1 (de) | Formulierung für rekombinantes beta-interferon, verfahren zur gewinnung und stabilisierung des beta-interferons und dessen verwendung. | |
| ATE66817T1 (de) | Stabile formulierung biologisch aktiver proteine zur parenteralen injektion. | |
| EP0374257B1 (en) | STABLE INTERFERON $g(b) COMPOSITION | |
| DK1381432T3 (da) | HSA-frie interferon-beta-præparater | |
| LU88761I2 (fr) | Interferon-beta 1b et ses dérivés pharmaceutiquement acceptables (Betaferon (R)) | |
| EE05201B1 (et) | Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks | |
| ATE224726T1 (de) | Flüssige interferon-beta-formulierungen | |
| CY1110352T1 (el) | Αντι-ιικος παραγοντας υπο τη μορφη ρινικων σταγονων | |
| DK0759775T3 (da) | Flydende IFN-beta-formuleringer | |
| FI915654A0 (fi) | Somatotropiner med alterneringar i alfahelixregionen 1 och kombinationer med andra mutationer. | |
| FI822331A0 (fi) | Blandningar foer lokal anvaendning pao huden | |
| DK0456153T3 (da) | Galeniske vandige formuleringer af erythopoietin og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ATS | Application withdrawn |